长春瑞滨联合卡培他滨治疗转移性乳腺癌30例临床观察

目的观察长春瑞滨联合卡培他滨对蒽环类药物治疗后无效或复发的转移性乳腺癌的疗效.方法转移性乳腺癌患者30例,长春瑞滨20 mg/m2第1天和第8天静脉滴注,卡培他滨每天1 250 mg/m2,分早晚两次服用,连续服用2周,3周为一个周期.结果 CR 1例(33.3%),PR 7例(23.3%),MR 7例(23.3%),SD 7例(23.3%),PD 8例(26.7%),有效率达49.9%,中位缓解期4.6个月(2～13个月).常见的不良反应为骨髓抑制、胃肠道反应、手足综合征、神经毒性等.结论长春瑞滨联合卡培他滨对蒽环类药物治疗后失败的转移性乳腺癌有较好的疗效,毒性可以耐受.

Vinorelbine combined with capecitabine in the treatment of advanced and metastatic breast cancer

Objective To evaluate the re sults of combination chemotherapy with vinorelbine and capecitabine in the treat ment of adbanced breast cancer. Methods Thirty patients o f metastatic breast cancer received vinorelbine 20 mg/m2 on day 1 and day 8 iv gett, cycles were repeated every 21 days. Patients received capecitabine 1 250 mg/m2/d twice daily for 2 week followed by a 1 week rest period. Results Complete response in one patient, partial response in seve n patients, minor response in seven patients, stable disease in seven patients and progressive disease in eight patients were observed. Overall responsed rate was 49.9%. The common side effects were neutropenia, nausea, vomitimg, hand- foot syndrome, neural toxicity. Conclusion Vinorelbine an d capecitabine combination regimen has good anti-tumor activity on patients who were failure from the treatment of doxorubicin. The adverse reactions were toler able to the majority of patients.